Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2016, Vol. 10 Issue (4) : 490-498     DOI: 10.1007/s11684-016-0470-y
Immunogenicity and protective immunity against otitis media caused by pneumococcus in mice of Hib conjugate vaccine with PsaA protein carrier
Zeyu Chen1,2(),Rong Guo3,Jianghong Xu1,2,Chuangjun Qiu4
1. Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai 200031, China
2. Shanghai Clinical Medical Center of Hearing Medicine, Shanghai 200031, China
3. The Laboratory of Bacterial Vaccine, Wuhan Institute of Biological Products, Wuhan 430207, China
4. Dingtai-Haigui Biotechnology Co. Ltd., Gu’an 065500, China
Download: PDF(333 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

This study evaluated the immunogenicity and protective immunity of a Hemophilus influenzae b (Hib) polysaccharide conjugate vaccine with the pneumococcal surface adhesin A (PsaA) protein carrier in young mice. The Hib polysaccharide was conjugated with the rPsaA protein carrier, which was produced using recombinant DNA technology. A total of 15 young mice aged 3 weeks to 5 weeks were immunized with the conjugate vaccine, and another 15 young mice of the same age were immunized with the licensed Hib-tetanus toxoid (TT) vaccine. Furthermore, the third group of 15 young mice was inoculated with phosphate buffer saline as control. The immunized mice were inoculated with pneumococcus in the middle ear. Results showed that IgG antibody responses against both the PsaA protein and Hib polysaccharide were observed in the Hib-PsaA group. However, no statistical difference was observed in the titer of IgG against the Hib polysaccharide between Hib-PsaA and Hib-TT groups. The elimination rate of pneumococcus and the inflammation of the middle ear showed the effectiveness of protective immunity against otitis media caused by pneumococcus. Our results suggest that the Hib polysaccharide can be successfully conjugated with rPsaA via amide condensation. This new Hib-PsaA conjugate vaccine can induce both anti-PsaA and anti-Hib immune responses in young mice and elicit effective protection against acute otitis media caused by pneumococcus.

Keywords conjugate vaccine      pneumococcal surface adhesin A      Hemophilus influenzae b      immunogenicity      otitis media     
Corresponding Authors: Zeyu Chen   
Just Accepted Date: 19 August 2016   Online First Date: 20 September 2016    Issue Date: 01 December 2016
URL:     OR
Fig.1  PCR amplification of the PsaA gene. Line M, marker; Line PsaA, PsaA gene.
Fig.2  Identification of the purity of rPsaA protein with SDS-PAGE. Line 1, the first 1 ml eluent eluted by 20 mmol/L imidazole; Line 2, the second 1 ml eluent eluted by 20 mmol/L imidazole; Line 3, the third 1 ml eluent eluted by 20 mmol/L imidazole; Line 4, the fourth 1 ml eluent eluted by 20 mmol/L imidazole; Line 5: the fifth 1 ml eluent eluted by 20 mmol/L imidazole; Line 6, the first 1 ml eluent eluted by 200 mmol/L imidazole; Line 7, the second 1 ml eluent eluted by 200 mmol/L imidazole; Line 8, the third 1 ml eluent eluted by 200 mmol/L imidazole; Line 9, the fourth 1 ml eluent eluted by 200 mmol/L imidazole; Line M, protein marker.
Fig.3  Chromatography of rPsaA obtained by using a Sepharose 4FF column.
Fig.4  Chromatography of the rPsaA-Hib polysaccharide conjugate obtained by using a Sepharose 4FF column.
GMT of anti-PsaA IgG
GMT of anti-Hib IgG
Hib-PsaA group 68.42±15.55 51.64±16.91
Hib-TT group
Control group
Tab.1  Serum antibody titers of IgG against PsaA and IgG against Hib polysaccharide for each group of mice after immunization
Fig.5  GMT of anti-PsaA IgG and anti-Hib polysaccharide IgG. 1, GMT of anti-PsaA IgG; 2, GMT of anti-Hib polysaccharide IgG.
Fig.6  Histopathological changes of the middle ear of mice three and seven days after the challenge with pneumococcus (HE staining, 50 ×). (A) Three days after challenge, Hib-PsaA group. (B) Three days after challenge, PBS group. (C) Seven days after challenge, Hib-PsaA group. (D) Seven days after challenge, PBS group.
Fig.7  Histopathological changes of the drum membrane of mice three and seven days after challenge with pneumococcus (HE staining, 50×; the arrow indicates the drum membrane). (A) Three days after challenge, Hib-PsaA group. (B) Three days after challenge, PBS group. (C) Seven days after challenge, Hib-PsaA group. (D) Seven days after challenge, PBS group.
1 Hasegawa J, Mori M, Showa S, Matsushima A, Ohnishi H, Tsugawa T, Yoto Y, Tsutsumi H. Pneumococcal vaccination reduced the risk of acute otitis media: cohort study. Pediatr Int 2015; 57(4): 582–585
doi: 10.1111/ped.12587 pmid: 25615843
2 Intakorn P, Sonsuwan N, Noknu S, Moungthong G, Pirçon JY, Liu Y, Van Dyke MK, Hausdorff WP. Haemophilus influenzae type b as an important cause of culture-positive acute otitis media in young children in Thailand: a tympanocentesis-based, multi-center, cross-sectional study. BMC Pediatr 2014; 14(1): 157
doi: 10.1186/1471-2431-14-157 pmid: 24947736
3 Kim KH, Lee H, Chung EH, Kang JH, Kim JH, Kim JS, Lee HJ, Oh SH, Park EA, Park SE. Immunogenicity and safety of two different Haemophilus influenzae type b conjugate vaccines in Korean infants. J Korean Med Sci 2008; 23(6): 929–936
doi: 10.3346/jkms.2008.23.6.929 pmid: 19119431
4 Yatsyshina S, Mayanskiy N, Shipulina O, Kulichenko T, Alyabieva N, Katosova L, Lazareva A, Skachkova T, Elkina M, Matosova S, Shipulin G. Detection of respiratory pathogens in pediatric acute otitis media by PCR and comparison of findings in the middle ear and nasopharynx. Diagn Microbiol Infect Dis 2016; 85(1): 125–130
doi: 10.1016/j.diagmicrobio.2016.02.010 pmid: 26971180
5 Pumarola F, Marès J, Losada I, Minguella I, Moraga F, Tarragó D, Aguilera U, Casanovas JM, Gadea G, Trías E, Cenoz S, Sistiaga A, García-Corbeira P, Pirçon JY, Marano C, Hausdorff WP. Microbiology of bacteria causing recurrent acute otitis media (AOM) and AOM treatment failure in young children in Spain: shifting pathogens in the post-pneumococcal conjugate vaccination era. Int J Pediatr Otorhinolaryngol 2013; 77(8): 1231–1236
doi: 10.1016/j.ijporl.2013.04.002 pmid: 23746414
6 Dagan R, Eskola J, Leclerc C, Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 1998; 66(5): 2093–2098
pmid: 9573094
7 Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci 1995; 754(1 Combined Vacc): 35–47
doi: 10.1111/j.1749-6632.1995.tb44436.x pmid: 7625671
8 Sabirov A, Kodama S, Hirano T, Suzuki M, Mogi G. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun 2001; 69(5): 2964–2971
doi: 10.1128/IAI.69.5.2964-2971.2001 pmid: 11292713
9 Sipilä M, Pukander J, Karma P. Incidence of acute otitis media up to the age of 1 1/2 years in urban infants. Acta Otolaryngol 1987; 104(1-2): 138–145
doi: 10.3109/00016488709109059 pmid: 3661155
10 Faden H, Duffy L, Boeve M. Otitis media: back to basics. Pediatr Infect Dis J 1998; 17(12): 1105–1112, quiz 1112–1113
doi: 10.1097/00006454-199812000-00002 pmid: 9877357
11 Qureishi A, Lee Y, Belfield K, Birchall JP, Daniel M. Update on otitis media —prevention and treatment. Infect Drug Resist 2014; 7(1): 15–24
pmid: 24453496
12 Dowell SF, Butler JC, Giebink GS, Jacobs MR, Jernigan D, Musher DM, Rakowsky A, Schwartz B. Acute otitis media: management and surveillance in an era of pneumococcal resistance—a report from the Drug-resistant Streptococcus pneumoniae Therapeutic Working Group. Pediatr Infect Dis J 1999; 18(1): 1–9
doi: 10.1097/00006454-199901000-00002 pmid: 9951971
13 O’Brien KL, Dagan R, Mäkelä PH. Nasopharyngeal carriage. In: Siber GR, Klugman KP, Mäkelä PH. Pneumococcal Vaccines: the Impact of Conjugate Vaccine. Washington, DC: ASM Press, 2008:279–300
14 Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995; 33(10): 2759–2762
pmid: 8567920
15 Dhooge IJ, van Kempen MJ, Sanders LA, Rijkers GT. Deficient IgA and IgG2 anti-pneumococcal antibody levels and response to vaccination in otitis prone children. Int J Pediatr Otorhinolaryngol 2002; 64(2): 133–141
doi: 10.1016/S0165-5876(02)00068-X pmid: 12049826
16 Sniadack DH, Schwartz B, Lipman H, Bogaerts J, Butler JC, Dagan R, Echaniz-Aviles G, Lloyd-Evans N, Fenoll A, Girgis NI, Henrichsen J, Klugman K, Lehmann D, Takala AK, Vandepitte J, Gove S, Breiman RF. Potential interventions for the prevention of childhood pneumonia: geographic and temporal differences in serotype and serogroup distribution of sterile site pneumococcal isolates from children—implications for vaccine strategies. Pediatr Infect Dis J 1995; 14(6): 503–510
doi: 10.1097/00006454-199506000-00007 pmid: 7667055
17 Briles DE, Hollingshead SK, Crain MJ, Ren B, Mirza S, Watt J, Johnston J. Pneumococcal proteins that may constitute the next generation vaccine for pneumococcal disease. Int Congr Ser 2003; 1257: 27–31
doi: 10.1016/S0531-5131(03)01157-9
18 Briles DE, Hollingshead S, Brooks-Walter A, Nabors GS, Ferguson L, Schilling M, Gravenstein S, Braun P, King J, Swift A. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 2000; 18(16): 1707–1711
doi: 10.1016/S0264-410X(99)00511-3 pmid: 10689153
19 Bogaert D, Hermans PW, Adrian PV, Rümke HC, de Groot R. Pneumococcal vaccines: an update on current strategies. Vaccine 2004; 22(17-18): 2209–2220
doi: 10.1016/j.vaccine.2003.11.038 pmid: 15149779
20 Briles DE, Hollingshead SK, Nabors GS, Paton JC, Brooks-Walter A. The potential for using protein vaccines to protect against otitis media caused by Streptococcus pneumoniae. Vaccine 2000; 19(Suppl 1): S87–S95
doi: 10.1016/S0264-410X(00)00285-1 pmid: 11163470
21 Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978–1994: implications for development of a conjugate vaccine. J Infect Dis 1995; 171(4): 885–889
doi: 10.1093/infdis/171.4.885 pmid: 7706815
22 Mayanskiy N, Alyabieva N, Ponomarenko O, Pakhomov A, Kulichenko T, Ivanenko A, Lazareva M, Lazareva A, Katosova L, Namazova-Baranova L, Baranov A. Bacterial etiology of acute otitis media and characterization of pneumococcal serotypes and genotypes among children in Moscow, Russia. Pediatr Infect Dis J 2015; 34(3): 255–260
doi: 10.1097/INF.0000000000000554 pmid: 25232779
No related articles found!
Full text